Loading...
The Financial Express

Russia authorises single-dose Sputnik Light Covid vaccine for use

| Updated: May 07, 2021 17:39:01


A view shows samples of Sputnik Light vaccine against the coronavirus disease (Covid-19) developed by the Gamaleya Research Institute of Epidemiology and Microbiology, in this still image taken from video released May 6, 2021 by the Russian Direct Investment Fund (RDIF) A view shows samples of Sputnik Light vaccine against the coronavirus disease (Covid-19) developed by the Gamaleya Research Institute of Epidemiology and Microbiology, in this still image taken from video released May 6, 2021 by the Russian Direct Investment Fund (RDIF)

Russia has authorised the one-shot Sputnik Light version of its Covid-19 vaccine for use, the Russian Direct Investment Fund (RDIF) said on Thursday, a move that could help vaccine supplies go further in countries with high infection rates.

Developed by Moscow's Gamaleya Institute, the slimmed-down vaccine, which the RDIF said is 79.4 per cent effective against Covid-19 and costs under $10 a dose, has been earmarked for export and could increase the number of people with partial immunity.

One of its main potential uses is as a vaccine that can be shipped to a country in the grip of an acute outbreak which needs to be subdued quickly.

"The single-dose Sputnik Light vaccine demonstrated 79.4 percent efficacy according to analysed data taken from 28 days after the injection was administered as part of Russia's mass vaccination programme between 5 December 2020 and 15 April 2021," the RDIF said in a statement.

A Phase III clinical trial involving 7,000 people was under way in Russia, the United Arab Emirates, Ghana and other countries, the RDIF said. Interim results are expected later this month.

Share if you like